Handok-Genexine co-develop growth hormone, selected as orphan drug from FDA

‘GX-H9,’ a long-acting growth hormone that is being co-developed by Handok(Chairman Young-Jin Kim) and Genexine(CEO Han-Soo Kyung), was selected as an orphan drug to treat growth hormone deficiency from the U.S. Food and Drug Administration(FDA) on the 9^th of November.  

Growth hormone is a protein hormone product that is widely used not only for diseases such as growth retardation and develop...